Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity‐modulated chemoradiation. Issue 12 (18th March 2013)

• Record Type: Journal Article
• Authors: Broglie, Martina A.; Soltermann, Alex; Rohrbach, David; Haile, Sarah R.; Pawlita, Michael; Studer, Gabriela; Huber, Gerard F.; Moch, Holger; Stoeckli, Sandro J.
• Is Part Of: Head & neck. Volume 35:Issue 12(2013:Dec.)
• Page Start: 1698
• Page End: 1706
• Publication Date: 2013-03-18
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23231
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hed23231-sec-0001" sec-type="section"> <title>Background</title> <p>Analysis of the impact of risk factors on survival in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated by primary intensity‐modulated radiotherapy (IMRT).</p> </sec> <sec id="hed23231-sec-0002" sec-type="section"> <title>Methods</title> <p>One hundred forty patients were included with tissue microarray (TMA) construction and immunohistochemical analysis in 124 patients (87%).</p> </sec> <sec id="hed23231-sec-0003" sec-type="section"> <title>Results</title> <p>Survival analysis of patients classified into 3 risk categories according to an algorithm based on p16, smoking, T classification, and N classification revealed significant differences with a low, intermediate, and high‐risk group. There was a significant impact of p53 expression as surrogate marker for smoking on outcome. In multivariate analysis, p16‐positivity was a positive predictor and alcohol as well as N classification was a negative predictor for survival. The algorithm was modified based on alcohol instead of smoking with even more significant differences between the groups.</p> </sec> <sec id="hed23231-sec-0004" sec-type="section"> <title>Conclusions</title> <p>A risk model based on multiple factors instead of p16 as single marker can define different risk groups to select patients for treatment deintensification in future prospective clinical trials. © 2013 Wiley Periodicals, Inc. <italic>Head Neck</italic> 35: 1698–1706, 2013</p> </sec> </abstract>